Results 91 to 100 of about 5,328 (197)

Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections

open access: yes, 2016
12p.-7 fig.-2 tab.Drug-loaded nanoparticles (NPs) can improve infection treatment by ensuring drug concentration at the right place within the therapeutic window.
Domenech, Mirian   +11 more
core   +1 more source

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells

open access: yesFrontiers in Oncology, 2019
Prima-1Met (APR-246) was previously shown to be dependent on glutathione inhibition and on ROS induction in cancer cells with mutated or deleted TP53.
Benoit Tessoulin   +15 more
doaj   +1 more source

Anticancer auranofin engages 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) as a target

open access: yes, 2019
Auranofin (AuRF) has been reported to display anticancer activity and has entered several clinical trials; however, its mechanism of action remains largely unknown.
Che, CM   +4 more
core   +1 more source

Auranofin in the treatment of steroid dependent asthma: a double blind study

open access: yes, 1992
Long term administration of oral corticosteroids in patients with asthma may be associated with serious side effects. Non-steroidal anti-inflammatory drugs, including gold salts, have been shown to reduce the need for systemic corticosteroid treatment in
Zwinderman, A. H.   +4 more
core   +1 more source

Inhibition of S. japonicum adult worms by auranofin in vitro.

open access: yes, 2013
(A) Effects of auranofin (AUF 1, 5, 10, 20, 30 µg/ml) on TrxR and GR activities of adult worms after 3 h of treatment. Worms were mock treated in the control groups (RPMI 1640 and 1.2% DMSO). Worms were treated with 30 µg/ml of praziquantel in the PZQ 30
JiaHuang Li (5652532)   +8 more
core   +1 more source

Publication Only

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

TEM images of auranofin treated B. pahangi.

open access: yes, 2015
Transmission electron microscopy of auranofin treated versus control adult female Brugia pahangi after overnight drug treatment. (A) B. pahangi treated with 1 μM of auranofin. Hypodermal chord region (h) below cuticle (cu) of B.
Jiri Gut (145726)   +24 more
core   +1 more source

Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci

open access: yes, 2018
Multidrug-resistant enterococcal pathogens, especially vancomycin-resistant enterococci (VRE), are among the pathogens that require new antibiotic innovation.
Mohamed N. Seleem   +3 more
core   +1 more source

Repurposing auranofin to treat Clostridium difficile infection by targeting selenium

open access: yes, 2017
This research investigated the role of selenoproteins in the bacterial human pathogen Clostridium difficile and tested auranofin as a treatment for this infection.
Christine Roder (13065378)
core  

Auranofin inhibits the active uptake of bile acid by rat ileum

open access: yes, 1987
Auranofin in the mucosal fluid inhibited the active Na+-dependent absorption of taurocholic acid by everted sacs of rat ileum. It did not however, affect the passive uptake of taurocholic acid by sacs of mid-intestine.
P T Hardcastle   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy